Please login to the form below

Not currently logged in
Email:
Password:

Bristol-Myers Squibb cuts workforce by 10 per cent

Global biopharmaceutical company Bristol-Myers Squibb has announced that it is to cut its workforce by a further 10 per cent by 2010

Global biopharmaceutical company Bristol-Myers Squibb has announced that it is to cut its workforce by a further 10 per cent by 2010.

In December 2007, the company announced a $1.5bn productivity transformation initiative to be completed by 2010. These latest cuts are part of planned additional savings of $1bn by 2012 and form part of productivity initiatives first announced by the company in July 2008.

Speaking in July, Jean-Marc Huet, senior vice president and chief financial officer said: "As part of the plan to maximize our growth opportunities through 2011 and improve our earnings base in 2012-2013, we have initiated an expansion of our productivity initiatives which will result in an additional $1bn of cost savings by 2012."

Bristol-Myers Squibb is one of several global pharmaceutical companies facing patents for several of its top-selling drugs expiring shortly, and having to deal with competition in the market from generic manufacturers.
 

17th December 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics